Kwality Pharmaceuticals' Q2 FY 2026-27 Quarterly Results

Result Summary

• Kwality Pharmaceuticals Ltd reported a 11.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 62.6%.
• Its expenses for the quarter were up by 8.4% QoQ and 49.5% YoY.
• The net profit increased 13.3% QoQ and increased 105.6% YoY.
• The earnings per share (EPS) of Kwality Pharmaceuticals Ltd stood at 27.93 during Q2 FY 2026-27.

Financial Statments for Q2 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Kwality Pharmaceuticals Ltd is a company operating primarily in the pharmaceutical industry. It is involved in the manufacturing and distribution of pharmaceutical products, focusing on a range of therapeutic areas. The company is known for its diverse product portfolio, which includes formulations across various segments such as tablets, capsules, injectables, and syrups. Kwality Pharmaceuticals Ltd has positioned itself as a key player in the pharmaceutical sector, with a commitment to quality and affordability. However, recent major developments in the company are not available based on the provided data.

Revenue

In the second quarter of the fiscal year 2027 (Q2FY27), Kwality Pharmaceuticals Ltd reported a total income of ₹181.99 crores. This represents a significant increase of 11.7% compared to the previous quarter, Q1FY27, where the total income was ₹162.97 crores. Moreover, there was a substantial year-over-year (YoY) growth of 62.6% when compared to Q2FY26, where the total income stood at ₹111.95 crores. This marked growth in revenue indicates a robust performance over both the sequential and annual periods, reflecting the company’s capacity to enhance its sales and revenue streams.

Profitability

The company’s profitability metrics for Q2FY27 reveal a positive trajectory. Profit Before Tax (PBT) was reported at ₹42.22 crores, showing a quarter-over-quarter (QoQ) increase of 24.2% from ₹33.99 crores in Q1FY27. Year-over-year, the PBT rose by a significant 128.8% from the ₹18.45 crores recorded in Q2FY26. After accounting for taxes, Profit After Tax (PAT) was ₹29.03 crores for Q2FY27, which is a 13.3% increase from ₹25.62 crores in the previous quarter and a 105.6% increase from ₹14.12 crores in Q2FY26. The Earnings Per Share (EPS) also showed a positive trend, increasing by 13.1% QoQ from ₹24.69 to ₹27.93 and 105.4% YoY from ₹13.60. This demonstrates a marked improvement in profitability metrics over both quarterly and annual periods.

Operating Metrics

Analyzing the operating metrics, Kwality Pharmaceuticals Ltd’s total expenses for Q2FY27 were ₹139.77 crores, reflecting an 8.4% increase from ₹128.98 crores in Q1FY27. On a year-over-year basis, total expenses rose by 49.5% from ₹93.50 crores in Q2FY26. The tax expenditure for the quarter was ₹13.19 crores, which increased by 57.8% QoQ from ₹8.36 crores in Q1FY27, and 204.6% YoY from ₹4.33 crores in Q2FY26. These metrics highlight the company's operational scale and cost management during the period under review.